Published: August 12, 2010
First Patient Implanted in Investigational Study for Self Sealing GORE ACUSEAL Vascular Graft
FLAGSTAFF, Ariz. - (BUSINESS WIRE) - W.
L. Gore & Associates (Gore) reported that the first patient, in
an Investigational Device Exemption (IDE) clinical study evaluating the
self sealing GORE ACUSEAL Vascular Graft in patients on
hemodialysis, has been surgically implanted with the device. The
successful surgical procedure was performed on July 29, 2010 at
Greenville Hospital System in Greenville, South Carolina. Less than 24
hours after the device was implanted it was successfully cannulated or
punctured for initial hemodialysis access.
David L. Cull, MD, Interim Chair Department of Surgery at the Greenville
Hospital, surgically implanted the GORE ACUSEAL Vascular
Graft in the upper extremity of an End Stage Renal Disease (ESRD)
patient. ESRD patients frequently require prosthetic tube-shaped
conduits to access their blood for hemodialysis. The GORE ACUSEAL
Vascular Graft features a multi-layer wall construction engineered to
minimize bleeding during the implant procedure and during the subsequent
needle punctures required to access a patient's blood during dialysis
sessions.
"ESRD patients can pose significant treatment challenges, including the
healing and early sealing of vascular grafts," said Dr. Cull, who is an
investigator for the U.S. Food & Drug Administration (FDA) sanctioned
IDE clinical study. "The concept behind this new product is the blending
of self sealing with an optimal handling vascular graft compatible with
a patient's native blood vessels."
The GORE ACUSEAL Vascular Graft Clinical Study will evaluate the safety
and efficacy of the GORE ACUSEAL Vascular Device. 138 patients will be
enrolled at research sites across the United States. The primary
efficacy endpoint of the study will look at patency with a secondary
endpoint of monitoring the amount of time to central venous catheter
removal for applicable cases. Study subjects who receive the GORE
ACUSEAL Vascular Graft can begin receiving hemodialysis through the
device at any time in the early postoperative period and when their
physician feels it to be appropriate.
The GORE ACUSEAL Vascular Graft is the only prosthetic vascular graft to
combine predictable self-sealing with improved handling and a surface
bonded with heparin. Featuring expanded polyetrafluoroethylene (ePTFE)
on the external and luminal surfaces, the middle layer of the graft is a
self sealing elastomer. This unique construction inhibits blood leakage
following suturing of the vascular graft or after the repeated needle
cannulations necessary for hemodialysis access treatments.
ABOUT W. L. GORE & ASSOCIATES
The Gore Medical Products Division has provided creative therapeutic
solutions to complex medical problems for three decades. During that
time, more than 25 million innovative Gore Medical Devices have been
implanted, saving and improving the quality of lives worldwide. The
extensive Gore Medical family of products includes vascular grafts,
endovascular and interventional devices, surgical meshes for hernia
repair, soft tissue reconstruction, staple line reinforcement and
sutures for use in vascular, cardiac and general surgery. Gore was
recently named one of the best companies to work for by Fortune magazine
for the 13th consecutive year. For more information, visit www.goremedical.com.
Products listed may not be available in all markets. GORE,
ACUSEAL, and designs are trademarks of W. L. Gore & Associates.
AP4469-EN1 AUGUST 2010

College Hill Life Sciences for W. L. Gore & Associates
Erik
Clausen or Kena Hudson, 415-230-5385
GoreMedical@CollegeHill.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News